IMRX
Immuneering Corporation
NASDAQ · Healthcare · Biotechnology · US
$4.82
−4.37%Aug 5, 2026, 11:30 UTC
Immuneering Corporation reported its financial results for the second quarter ended June 30, 2026, ending with $182.7 million in cash, cash equivalents and marketable securities with anticipated runway into 2029.
Source:Jun 15, 2026, 11:55 UTC
Immuneering Corporation appointed Andrew Gengos as Chief Financial Officer, effective July 16.
Source:Jun 12, 2026, 14:51 UTC
Immuneering (IMRX) began dosing the first patient in a pivotal Phase III study of atebimetinib plus mGnP for first-line metastatic pancreatic cancer.
Source:Jun 11, 2026, 11:30 UTC
Immuneering Corporation dosed the first patient in its pivotal Phase 3 MAPKeeper 301 trial of atebimetinib plus mGnP for first-line pancreatic cancer.
Source:Jun 1, 2026, 11:30 UTC
Immuneering presented clinical data for atebimetinib plus chemotherapy in first-line pancreatic cancer at ASCO.
Source: